Skip to main content
Top
Published in: Pediatric Drugs 6/2013

01-12-2013 | Current Opinion

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

Authors: Olympia A. Tsilochristou, Nikolaos Douladiris, Michael Makris, Nikolaos G. Papadopoulos

Published in: Pediatric Drugs | Issue 6/2013

Login to get access

Abstract

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of ‘united airways disease’ or ‘respiratory allergy’, implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the ‘atopic march’. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.
Literature
1.
go back to reference Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160. doi:10.1111/j.1398-9995.2007.01620.x.PubMed Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160. doi:10.​1111/​j.​1398-9995.​2007.​01620.​x.PubMed
2.
go back to reference Grossman J. One airway, one disease. Chest. 1997;111(2 Suppl):11S–6S.PubMed Grossman J. One airway, one disease. Chest. 1997;111(2 Suppl):11S–6S.PubMed
3.
go back to reference Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol. 1999;104(3 Pt 1):534–40.PubMed Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol. 1999;104(3 Pt 1):534–40.PubMed
4.
go back to reference Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol. 2001;1(1):7–13.PubMed Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol. 2001;1(1):7–13.PubMed
5.
go back to reference Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003;111(6):1171–83 quiz 84.PubMed Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003;111(6):1171–83 quiz 84.PubMed
7.
go back to reference Leynaert B, Neukirch C, Kony S, Guenegou A, Bousquet J, Aubier M, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol. 2004;113(1):86–93. doi:10.1016/j.jaci.2003.10.010.PubMed Leynaert B, Neukirch C, Kony S, Guenegou A, Bousquet J, Aubier M, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol. 2004;113(1):86–93. doi:10.​1016/​j.​jaci.​2003.​10.​010.PubMed
8.
go back to reference Pedersen PA, Weeke ER. Asthma and allergic rhinitis in the same patients. Allergy. 1983;38(1):25–9.PubMed Pedersen PA, Weeke ER. Asthma and allergic rhinitis in the same patients. Allergy. 1983;38(1):25–9.PubMed
9.
go back to reference Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351(9111):1225–32. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351(9111):1225–32.
10.
go back to reference Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998;12(2):315–35. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998;12(2):315–35.
11.
go back to reference Grize L, Gassner M, Wuthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH, et al. Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001. Allergy. 2006;61(5):556–62. doi:10.1111/j.1398-9995.2006.01030.x.PubMed Grize L, Gassner M, Wuthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH, et al. Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001. Allergy. 2006;61(5):556–62. doi:10.​1111/​j.​1398-9995.​2006.​01030.​x.PubMed
12.
13.
go back to reference Chawes BL, Bonnelykke K, Kreiner-Moller E, Bisgaard H. Children with allergic and nonallergic rhinitis have a similar risk of asthma. J Allergy Clin Immunol. 2010;126(3):567–73 e1-8. doi:10.1016/j.jaci.2010.06.026. Chawes BL, Bonnelykke K, Kreiner-Moller E, Bisgaard H. Children with allergic and nonallergic rhinitis have a similar risk of asthma. J Allergy Clin Immunol. 2010;126(3):567–73 e1-8. doi:10.​1016/​j.​jaci.​2010.​06.​026.
14.
go back to reference Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics. 1994;94(6 Pt 1):895–901.PubMed Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics. 1994;94(6 Pt 1):895–901.PubMed
15.
go back to reference Thomas M, Kocevar VS, Zhang Q, Yin DD, Price D. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics. 2005;115(1):129–34. doi:10.1542/peds.2004-0067.PubMed Thomas M, Kocevar VS, Zhang Q, Yin DD, Price D. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics. 2005;115(1):129–34. doi:10.​1542/​peds.​2004-0067.PubMed
16.
17.
go back to reference Burgess JA, Walters EH, Byrnes GB, Matheson MC, Jenkins MA, Wharton CL, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol. 2007;120(4):863–9. doi:10.1016/j.jaci.2007.07.020.PubMed Burgess JA, Walters EH, Byrnes GB, Matheson MC, Jenkins MA, Wharton CL, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol. 2007;120(4):863–9. doi:10.​1016/​j.​jaci.​2007.​07.​020.PubMed
18.
go back to reference Van Cauwenberge P, Watelet JB, Van Zele T, Wang DY, Toskala E, Durham S, et al. Does rhinitis lead to asthma? Rhinology. 2007;45(2):112–21.PubMed Van Cauwenberge P, Watelet JB, Van Zele T, Wang DY, Toskala E, Durham S, et al. Does rhinitis lead to asthma? Rhinology. 2007;45(2):112–21.PubMed
23.
go back to reference Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol. 2001;107(3):469–76. doi:10.1067/mai.2001.113046.PubMed Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol. 2001;107(3):469–76. doi:10.​1067/​mai.​2001.​113046.PubMed
24.
go back to reference Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med. 2000;161(6):2051–7. doi:10.1164/ajrccm.161.6.9906121.PubMed Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med. 2000;161(6):2051–7. doi:10.​1164/​ajrccm.​161.​6.​9906121.PubMed
25.
go back to reference Braunstahl GJ, Overbeek SE, Fokkens WJ, Kleinjan A, McEuen AR, Walls AF, et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med. 2001;164(5):858–65. doi:10.1164/ajrccm.164.5.2006082.PubMed Braunstahl GJ, Overbeek SE, Fokkens WJ, Kleinjan A, McEuen AR, Walls AF, et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med. 2001;164(5):858–65. doi:10.​1164/​ajrccm.​164.​5.​2006082.PubMed
26.
go back to reference Chanez P, Vignola AM, Vic P, Guddo F, Bonsignore G, Godard P, et al. Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am J Respir Crit Care Med. 1999;159(2):588–95. doi:10.1164/ajrccm.159.2.9801022.PubMed Chanez P, Vignola AM, Vic P, Guddo F, Bonsignore G, Godard P, et al. Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am J Respir Crit Care Med. 1999;159(2):588–95. doi:10.​1164/​ajrccm.​159.​2.​9801022.PubMed
29.
go back to reference Cuttitta G, Cibella F, La Grutta S, Hopps MR, Bucchieri S, Passalacqua G, et al. Non-specific bronchial hyper-responsiveness in children with allergic rhinitis: relationship with the atopic status. Pediatr Allergy Immunol. 2003;14(6):458–63.PubMed Cuttitta G, Cibella F, La Grutta S, Hopps MR, Bucchieri S, Passalacqua G, et al. Non-specific bronchial hyper-responsiveness in children with allergic rhinitis: relationship with the atopic status. Pediatr Allergy Immunol. 2003;14(6):458–63.PubMed
30.
go back to reference Linhares D, Jacinto T, Pereira AM, Fonseca JA. Effects of atopy and rhinitis on exhaled nitric oxide values—a systematic review. Clin Transl Allergy. 2011;1(1):8. doi:10.1186/2045-7022-1-8.PubMed Linhares D, Jacinto T, Pereira AM, Fonseca JA. Effects of atopy and rhinitis on exhaled nitric oxide values—a systematic review. Clin Transl Allergy. 2011;1(1):8. doi:10.​1186/​2045-7022-1-8.PubMed
34.
36.
go back to reference Wood RA, Johnson EF, Van Natta ML, Chen PH, Eggleston PA. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med. 1998;158(1):115–20.PubMed Wood RA, Johnson EF, Van Natta ML, Chen PH, Eggleston PA. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med. 1998;158(1):115–20.PubMed
37.
go back to reference Bjornsdottir US, Jakobinudottir S, Runarsdottir V, Juliusson S. The effect of reducing levels of cat allergen (Fel d 1) on clinical symptoms in patients with cat allergy. Ann Allergy Asthma Immunol. 2003;91(2):189–94.PubMed Bjornsdottir US, Jakobinudottir S, Runarsdottir V, Juliusson S. The effect of reducing levels of cat allergen (Fel d 1) on clinical symptoms in patients with cat allergy. Ann Allergy Asthma Immunol. 2003;91(2):189–94.PubMed
38.
go back to reference Ciprandi G, Ricca V, Tosca M, Landi M, Passalacqua G, Canonica GW. Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy. 1999;54(4):358–65.PubMed Ciprandi G, Ricca V, Tosca M, Landi M, Passalacqua G, Canonica GW. Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy. 1999;54(4):358–65.PubMed
39.
go back to reference Ciprandi G, Tosca M, Ricca V, Passalacqua G, Riccio AM, Bagnasco M, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy. 1997;27(10):1160–6.PubMed Ciprandi G, Tosca M, Ricca V, Passalacqua G, Riccio AM, Bagnasco M, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy. 1997;27(10):1160–6.PubMed
40.
go back to reference Vancheri C, Mastruzzo C, Tomaselli V, Bellistri G, Pistorio MP, Greco LR, et al. The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc. 2005;26(4):292–8.PubMed Vancheri C, Mastruzzo C, Tomaselli V, Bellistri G, Pistorio MP, Greco LR, et al. The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc. 2005;26(4):292–8.PubMed
41.
go back to reference Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1998;101(3):410–20. doi:10.1016/S0091-6749(98)70256-8.PubMed Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1998;101(3):410–20. doi:10.​1016/​S0091-6749(98)70256-8.PubMed
42.
go back to reference Grant JA, Nicodemus CF, Findlay SR, Glovsky MM, Grossman J, Kaiser H, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1995;95(5 Pt 1):923–32.PubMed Grant JA, Nicodemus CF, Findlay SR, Glovsky MM, Grossman J, Kaiser H, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1995;95(5 Pt 1):923–32.PubMed
43.
go back to reference Corren J, Harris AG, Aaronson D, Beaucher W, Berkowitz R, Bronsky E, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol. 1997;100(6 Pt 1):781–8.PubMed Corren J, Harris AG, Aaronson D, Beaucher W, Berkowitz R, Bronsky E, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol. 1997;100(6 Pt 1):781–8.PubMed
44.
go back to reference Van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L, Vincken W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J. 1997;10(10):2216–24.PubMed Van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L, Vincken W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J. 1997;10(10):2216–24.PubMed
45.
go back to reference Rédier H, Chanez P, De Vos C, Rifaï N, Clauzel AM, Michel FB, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol. 1992;90(2):215–24.PubMed Rédier H, Chanez P, De Vos C, Rifaï N, Clauzel AM, Michel FB, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol. 1992;90(2):215–24.PubMed
46.
go back to reference Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months’ treatment and 18 months’ posttreatment follow-up. J Allergy Clin Immunol. 2001;108(6):929–37. doi:10.1067/mai.2001.120015.PubMed Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months’ treatment and 18 months’ posttreatment follow-up. J Allergy Clin Immunol. 2001;108(6):929–37. doi:10.​1067/​mai.​2001.​120015.PubMed
47.
go back to reference Iikura Y, Naspitz CK, Mikawa H, Talaricoficho S, Baba M, Sole D, et al. Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy. 1992;68(3):233–6.PubMed Iikura Y, Naspitz CK, Mikawa H, Talaricoficho S, Baba M, Sole D, et al. Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy. 1992;68(3):233–6.PubMed
48.
go back to reference Bustos GJ, Bustos D, Romero O. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin Exp Allergy. 1995;25(6):568–73.PubMed Bustos GJ, Bustos D, Romero O. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin Exp Allergy. 1995;25(6):568–73.PubMed
49.
go back to reference Warner JO. Future aspects of pharmacological treatment to inhibit the allergic march. Pediatr Allergy Immunol. 2001;12(Suppl 14):102–7.PubMed Warner JO. Future aspects of pharmacological treatment to inhibit the allergic march. Pediatr Allergy Immunol. 2001;12(Suppl 14):102–7.PubMed
52.
go back to reference Gibbs BF, Levi-Schaffer F. H(4) receptors in mast cells and basophils: a new therapeutic target for allergy? Front Biosci. 2012;17:430–7. Gibbs BF, Levi-Schaffer F. H(4) receptors in mast cells and basophils: a new therapeutic target for allergy? Front Biosci. 2012;17:430–7.
53.
go back to reference Shiraishi Y, Jia Y, Domenico J, Joetham A, Karasuyama H, Takeda K, et al. Sequential engagement of FcεRI on mast cells and basophil histamine H(4) receptor and FcεRI in allergic rhinitis. J Immunol. 2013;190(2):539–48. doi:10.4049/jimmunol.1202049.PubMed Shiraishi Y, Jia Y, Domenico J, Joetham A, Karasuyama H, Takeda K, et al. Sequential engagement of FcεRI on mast cells and basophil histamine H(4) receptor and FcεRI in allergic rhinitis. J Immunol. 2013;190(2):539–48. doi:10.​4049/​jimmunol.​1202049.PubMed
54.
go back to reference Murphy K, Uryniak T, Simpson B, O’Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol. 2006;96(5):723–30. doi:10.1016/S1081-1206(10)61072-1.PubMed Murphy K, Uryniak T, Simpson B, O’Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol. 2006;96(5):723–30. doi:10.​1016/​S1081-1206(10)61072-1.PubMed
55.
go back to reference Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407–13.PubMed Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407–13.PubMed
56.
go back to reference Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2):E22.PubMed Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2):E22.PubMed
58.
go back to reference Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy. 2013;68(5):569–79. doi:10.1111/all.12124.PubMed Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy. 2013;68(5):569–79. doi:10.​1111/​all.​12124.PubMed
59.
go back to reference Ozturk F, Turktas I, Asal K, Ileri F, Munevver Pinar N. Effect of intranasal triamcinolone acetonide on bronchial hyper-responsiveness in children with seasonal allergic rhinitis and comparison of perceptional nasal obstruction with acoustic rhinometric assessment. Int J Pediatr Otorhinolaryngol. 2004;68(8):1007–15. doi:10.1016/j.ijporl.2004.03.006.PubMed Ozturk F, Turktas I, Asal K, Ileri F, Munevver Pinar N. Effect of intranasal triamcinolone acetonide on bronchial hyper-responsiveness in children with seasonal allergic rhinitis and comparison of perceptional nasal obstruction with acoustic rhinometric assessment. Int J Pediatr Otorhinolaryngol. 2004;68(8):1007–15. doi:10.​1016/​j.​ijporl.​2004.​03.​006.PubMed
60.
go back to reference Thio BJ, Slingerland GL, Fredriks AM, Nagelkerke AF, Scheeren RA, Neijens HJ, et al. Influence of intranasal steroids during the grass pollen season on bronchial responsiveness in children and young adults with asthma and hay fever. Thorax. 2000;55(10):826–32.PubMed Thio BJ, Slingerland GL, Fredriks AM, Nagelkerke AF, Scheeren RA, Neijens HJ, et al. Influence of intranasal steroids during the grass pollen season on bronchial responsiveness in children and young adults with asthma and hay fever. Thorax. 2000;55(10):826–32.PubMed
61.
go back to reference Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol. 2002;109(4):636–42.PubMed Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol. 2002;109(4):636–42.PubMed
62.
go back to reference Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol. 1993;91(1 Pt 1):97–101.PubMed Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol. 1993;91(1 Pt 1):97–101.PubMed
63.
go back to reference Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol. 1998;101(2 Pt 2):S352–6.PubMed Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol. 1998;101(2 Pt 2):S352–6.PubMed
64.
go back to reference Pedersen W, Hjuler I, Bisgaard H, Mygind N. Nasal inhalation of budesonide from a spacer in children with perennial rhinitis and asthma. Allergy. 1998;53(4):383–7.PubMed Pedersen W, Hjuler I, Bisgaard H, Mygind N. Nasal inhalation of budesonide from a spacer in children with perennial rhinitis and asthma. Allergy. 1998;53(4):383–7.PubMed
67.
go back to reference Ribeiro de Andrade C, Chatkin JM, Fiterman J, Scaglia N, Camargos PA. Unified disease, unified management: treating allergic rhinitis and asthma with nasally inhaled corticosteroid. Respir Med. 2010;104(10):1577–80. doi:10.1016/j.rmed.2010.06.021.PubMed Ribeiro de Andrade C, Chatkin JM, Fiterman J, Scaglia N, Camargos PA. Unified disease, unified management: treating allergic rhinitis and asthma with nasally inhaled corticosteroid. Respir Med. 2010;104(10):1577–80. doi:10.​1016/​j.​rmed.​2010.​06.​021.PubMed
68.
go back to reference Greiff L, Andersson M, Svensson C, Linden M, Wollmer P, Brattsand R, et al. Effects of orally inhaled budesonide in seasonal allergic rhinitis. Eur Respir J. 1998;11(6):1268–73.PubMed Greiff L, Andersson M, Svensson C, Linden M, Wollmer P, Brattsand R, et al. Effects of orally inhaled budesonide in seasonal allergic rhinitis. Eur Respir J. 1998;11(6):1268–73.PubMed
69.
go back to reference Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet. 2006;368(9537):754–62. doi:10.1016/S0140-6736(06)69285-4.PubMed Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet. 2006;368(9537):754–62. doi:10.​1016/​S0140-6736(06)69285-4.PubMed
70.
go back to reference Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985–97. doi:10.1056/NEJMoa051378.PubMed Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985–97. doi:10.​1056/​NEJMoa051378.PubMed
71.
go back to reference Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med. 2006;354(19):1998–2005. doi:10.1056/NEJMoa054692.PubMed Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med. 2006;354(19):1998–2005. doi:10.​1056/​NEJMoa054692.PubMed
72.
go back to reference Mygind N, Laursen LC, Dahl M. Systemic corticosteroid treatment for seasonal allergic rhinitis: a common but poorly documented therapy. Allergy. 2000;55(1):11–5.PubMed Mygind N, Laursen LC, Dahl M. Systemic corticosteroid treatment for seasonal allergic rhinitis: a common but poorly documented therapy. Allergy. 2000;55(1):11–5.PubMed
73.
go back to reference Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282–9 e10. doi:10.1016/j.jaci.2012.01.077. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282–9 e10. doi:10.​1016/​j.​jaci.​2012.​01.​077.
75.
76.
go back to reference Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67(6):887–901.PubMed Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67(6):887–901.PubMed
77.
go back to reference Li AM, Abdullah VJ, Tsen CS, Au CT, Lam HS, So HK, et al. Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis—a randomized placebo-controlled study. Pediatr Pulmonol. 2009;44(11):1085–92. doi:10.1002/ppul.21102.PubMed Li AM, Abdullah VJ, Tsen CS, Au CT, Lam HS, So HK, et al. Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis—a randomized placebo-controlled study. Pediatr Pulmonol. 2009;44(11):1085–92. doi:10.​1002/​ppul.​21102.PubMed
78.
go back to reference Razi C, Bakirtas A, Harmanci K, Turktas I, Erbas D. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(6):767–74. doi:10.1016/S1081-1206(10)60968-4.PubMed Razi C, Bakirtas A, Harmanci K, Turktas I, Erbas D. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(6):767–74. doi:10.​1016/​S1081-1206(10)60968-4.PubMed
79.
go back to reference Papadopoulos NG, Philip G, Giezek H, Watkins M, Smugar SS, Polos PG. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma. 2009;46(4):413–20. doi:10.1080/02770900902847727.PubMed Papadopoulos NG, Philip G, Giezek H, Watkins M, Smugar SS, Polos PG. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma. 2009;46(4):413–20. doi:10.​1080/​0277090090284772​7.PubMed
80.
go back to reference Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008;178(8):854–60. doi:10.1164/rccm.200706-910OC.PubMed Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008;178(8):854–60. doi:10.​1164/​rccm.​200706-910OC.PubMed
82.
go back to reference Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8. doi:10.1111/j.1398-9995.2007.01451.x.PubMed Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8. doi:10.​1111/​j.​1398-9995.​2007.​01451.​x.PubMed
84.
go back to reference Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6.PubMed Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6.PubMed
85.
go back to reference Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003;33(2):206–10.PubMed Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003;33(2):206–10.PubMed
86.
go back to reference Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7. doi:10.1016/j.jaci.2004.07.012.PubMed Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7. doi:10.​1016/​j.​jaci.​2004.​07.​012.PubMed
87.
go back to reference Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15(1):9–16.PubMed Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15(1):9–16.PubMed
88.
go back to reference Papadopoulos NG, Agache I, Bavbek S, Bilo BM, Braido F, Cardona V, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy. 2012;2(1):21. doi:10.1186/2045-7022-2-21.PubMed Papadopoulos NG, Agache I, Bavbek S, Bilo BM, Braido F, Cardona V, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy. 2012;2(1):21. doi:10.​1186/​2045-7022-2-21.PubMed
89.
go back to reference Valovirta E, Berstad AK, de Blic J, Bufe A, Eng P, Halken S, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther. 2011;33(10):1537–46. doi:10.1016/j.clinthera.2011.09.013.PubMed Valovirta E, Berstad AK, de Blic J, Bufe A, Eng P, Halken S, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther. 2011;33(10):1537–46. doi:10.​1016/​j.​clinthera.​2011.​09.​013.PubMed
90.
91.
go back to reference Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286(23):2956–67.PubMed Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286(23):2956–67.PubMed
92.
go back to reference Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24(5):323–9.PubMed Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24(5):323–9.PubMed
93.
go back to reference Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106(2):253–9. doi:10.1067/mai.2000.108310.PubMed Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106(2):253–9. doi:10.​1067/​mai.​2000.​108310.PubMed
94.
go back to reference Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(2):160–7. doi:10.1016/S1081-1206(10)62171-0.PubMed Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(2):160–7. doi:10.​1016/​S1081-1206(10)62171-0.PubMed
95.
go back to reference Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274–80.PubMed Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274–80.PubMed
96.
go back to reference Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004;59(9):973–9. doi:10.1111/j.1398-9995.2004.00552.x.PubMed Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004;59(9):973–9. doi:10.​1111/​j.​1398-9995.​2004.​00552.​x.PubMed
97.
go back to reference Kopp MV, Stenglein S, Kamin W, Friedrichs F, von Berg A, Zielen S, et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol. 2007;18(6):523–7. doi:10.1111/j.1399-3038.2007.00557.x.PubMed Kopp MV, Stenglein S, Kamin W, Friedrichs F, von Berg A, Zielen S, et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol. 2007;18(6):523–7. doi:10.​1111/​j.​1399-3038.​2007.​00557.​x.PubMed
98.
go back to reference Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;110(5):728–35.PubMed Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;110(5):728–35.PubMed
99.
100.
104.
go back to reference Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9. doi:10.1016/S0140-6736(12)60988-X.PubMed Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9. doi:10.​1016/​S0140-6736(12)60988-X.PubMed
105.
106.
go back to reference Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–95 e1-8. doi:10.1016/j.jaci.2011.07.056. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–95 e1-8. doi:10.​1016/​j.​jaci.​2011.​07.​056.
107.
go back to reference Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370(9596):1422–31. doi:10.1016/S0140-6736(07)61600-6.PubMed Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370(9596):1422–31. doi:10.​1016/​S0140-6736(07)61600-6.PubMed
108.
go back to reference Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res. 2007;62(2):215–20. doi:10.1203/PDR.0b013e3180a76d94.PubMed Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res. 2007;62(2):215–20. doi:10.​1203/​PDR.​0b013e3180a76d94​.PubMed
111.
Metadata
Title
Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?
Authors
Olympia A. Tsilochristou
Nikolaos Douladiris
Michael Makris
Nikolaos G. Papadopoulos
Publication date
01-12-2013
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2013
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-013-0043-3

Other articles of this Issue 6/2013

Pediatric Drugs 6/2013 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees